Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. is positioned positively due to the encouraging biomarker and safety data for its lead candidate PMN310, suggesting a mechanistic advantage that could enhance investor confidence ahead of forthcoming clinical data. The dual selectivity profile of PMN267 reveals its potential for broad application in TDP-43-driven neurodegenerative diseases, indicating significant development opportunities that could lead to substantial market demand. Furthermore, the absence of adverse effects typically associated with other marketed anti-amyloid treatments enhances PMN310's prospects, underscoring the company's strong developmental framework and its potential for sustained financial growth.

Bears say

ProMIS Neurosciences has reported a significant net loss of $11.6 million for the third quarter of 2025, translating to a loss of $0.24 per share, which underscores ongoing financial challenges and a lack of profitability. Furthermore, the company's reliance on complex mechanisms associated with Alzheimer's disease, such as soluble Aβ oligomers, raises concerns about the efficacy of its treatments, particularly given the history of failed therapies facing similar challenges. Additionally, the presence of potential partnership risks, competition impacting market uptake, and looming dilution risk may further hinder ProMIS's financial stability and stock performance.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.